Skip to main content
. 2017 Mar 28;24(7):1761–1769. doi: 10.1245/s10434-017-5820-8

Table 1.

Baseline, surgical, and histopathologic characteristics of 1701 patients treated with neoadjuvant chemotherapy followed by gastrectomy for cancer

Characteristic All (N = 1701) <5 weeks (n = 895) 5–8 weeks (n = 451) >8 weeks (n = 140) p
n % n (%) n (%) n (%)
Baseline characteristics
 Age, year, mean (±SD) 62.6 (±10.6) 62.4 (10.7) 63.2 (10.5) 62.4 (9.0) 0.386
 Gender 0.479
  Male 1064 (63) 548 (59) 287 (31) 92 (10)
  Female 637 (37) 347 (62) 164 (29) 48 (9)
 Malignancy history 0.934
  No 1546 (91) 814 (60) 409 (30) 126 (9)
  Yes 155 (9) 81 (59) 42 (31) 14 (10)
 Tumor differentiation 0.163
  Good to moderate 202 (20) 110 (21) 44 (17) 19 (26)
  Poor to undifferentiated 798 (80) 403 (79) 217 (83) 55 (74)
  Missing 701 382 190 66
 cT stage 0.399
  T1 44 (5) 22 (55) 12 (30) 6 (15)
  T2 439 (50) 235 (56) 138 (33) 45 (11)
  T3 304 (35) 158 (55) 97 (34) 30 (11)
  T4a 88 (10) 33 (45) 26 (36) 14 (19)
  Tx 826 447 178 45
 cN stage 0.466
  N0 951 (65) 504 (58) 277 (32) 82 (10)
  N+ 511 (35) 285 (62) 134 (29) 42 (9)
  Nx 239 106 40 16
 Year of diagnosis 0.268
  2006–2008 356 (21) 120 (59) 57 (28) 28 (14)
  2009–2011 616 (36) 339 (61) 170 (30) 49 (9)
  2012–2014 729 (43) 436 (60) 224 (31) 63 (9)
 Referral status <0.001
  Diagnosis in treatment hospital 1009 (69) 536 (53) 233 (23) 64 (6)
  Diagnosis in other hospital 445 (31) 211 (47) 144 (32) 53 (12)
  Missing 247 148 74 23
Treatment and histopathologic characteristics
 Surgical type 0.687
  Distal gastrectomy 924 (54) 487 (61) 236 (30) 77 (10)
  Total gastrectomy 749 (44) 394 (59) 211 (32) 62 (9)
  Multiorgan surgery 28 (2) 14 (74) 4 (21) 1 (5)
 Surgical approach 0.679
  Open 1447 (86) 742 (60) 373 (30) 119 (10)
  Laparoscopic 230 (14) 141 (62) 69 (30) 18 (8)
  Missing 24 12 9 3
 Radicality 0.782
  R0 1405 (86) 738 (60) 368 (30) 116 (9)
  R1–2 239 (15) 129 (61) 66 (31) 17 (8)
  Missing 57 28 17 7
 ypT stage <0.001
  T0 112 (7) 56 (57) 37 (37) 6 (6)
  T1 236 (14) 96 (48) 69 (34) 36 (18)
  T2 256 (15) 142 (62) 67 (29) 20 (9)
  T3 700 (42) 385 (62) 186 (30) 48 (8)
  T4a 309 (19) 162 (62) 73 (28) 25 (10)
  T4b 57 (3) 39 (74) 11 (21) 3 (6)
  Tx 31 15 8 2
 ypN stage 0.036
  N0 805 (47) 387 (55) 234 (33) 80 (11)
  N1 338 (20) 193 (67) 78 (27) 19 (7)
  N2 274 (16) 147 (63) 64 (28) 21 (9)
  N3 282 (17) 168 (64) 75 (29) 20 (8)
  Nx 2
 ypM stage 0.357
  M0 1625 (96) 885 (61) 438 (30) 135 (9)
  M1 76 (5) 40 (69) 13 (22) 5 (9)
 Curative intent 0.112
  Yes 1544 (92) 807 (57) 419 (30) 188 (13)
  No 127 (8) 74 (62) 24 (20) 21 (18)
  Missing 30 14 8 6
 90-day mortality 69 (4) 40 (4) 12 (3) 7 (5) 0.223
 Adjuvant therapy 0.009
  No 724 (43) 371 (59) 200 (32) 62 (10)
  Chemotherapy 783 (46) 429 (64) 185 (27) 61 (9)
  Radiotherapy 5 (<1) 2 (50) 0 (0) 2 (50)
  Chemoradiation 189 (11) 93 (53) 66 (38) 15 (9)